

Supplemental Material to:

**Reshma Rangwala, Robert Leone, Claire Chang,
Leslie Fecher, Lynn M Schuchter, Amy Kramer,
Kay-See Tan, Daniel F Hetjian, Glenda Rodgers,
Maryann Gallagher, Shengfu Piao, Andrea B Troxel,
Tracey Evans, Angela DeMichele, Katherine L Nathanson,
Peter J O'Dwyer, Jonathon Kaiser, Laura Pontiggia,
Lisa E Davis, and Ravi K Amaravadi**

**Phase I trial of hydroxychloroquine with dose-intense
temozolomide in patients with advanced solid tumors and
melanoma**

Autophagy 2014; 10(8)

<http://dx.doi.org/10.4161/auto.29118>

www.landesbioscience.com/journals/autophagy/article/29118

Supplemental Tables and Figure

Table S1. Melanoma patient demographics

Characteristic		Total
Number of patients		25
Age (years)	Median	61
	Range	(26-84)
Sex (%)	Male	69
	Female	31
AJCC stage, %	M1a or M1b	8
	M1c	92
ECOG PS, %	PS 0	75
	PS1	25
No. prior therapies, median		0
Prior chemotherapy, N (%)		9 (37%)
Prior anti-CTLA4 ab, N (%)		2 (8%)
LDH, %	<ULN	51
	≥ULN	49
Brain metastases, N(%)		12 (48%)
Genotype (N,%)	BRAF V600E	5/14 (36)
	Unavailable	11(44)
* <i>P</i> <0.05 compared to Arms A, B, D. AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Group; PS, performance status; ULN, upper limit of normal		

Table S2. Best response in patients with advanced melanoma.

<i>Dose level</i>	<i>N</i>	<i>CR</i>	<i>PR</i>	<i>SD</i>	<i>PD</i>	<i>NE</i>
200	1	0	0	0	1	0
400	2	0	0	1	1	1
800	8	0	2	2	4	3
1000	6	0	0	1	5	1
1200	5	0	1	2	2	2
Total	22	0/22	3/22	6/22	13/22	7

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable

Table S3. Dose-escalation		
Dose Level	HCQ (mg/day)^a	No. of patients^b
1	200	3
2	400	4
3	800	15
4	1000	7
5	1200	8
^a After a 2-week run in of HCQ alone, all patients received temozolomide 150 mg/m ² orally daily for 7 out of 14 days in addition to daily HCQ.		
^b Includes all patients who received at least one dose of HCQ.		
Abbreviations: HCQ, hydroxychloroquine		




Figure S1. Imaging results for a melanoma patient 3 weeks after discontinuing temozolomide and hydroxychloroquine. **(A)-(C)** positron emission tomography/computed tomography (PET/CT) imaging; **(A)** centrally photopenic fluoro-deoxyglucose (FDG)+ (SUV 10) lung tumor, **(B)** centrally necrotic FDG+ gastric tumor, **(C)** centrally necrotic FDG negative jejunal mass, **(D)** small bowel follow through demonstrating centrally necrotic jejunal mass.